Tolerability and effectiveness of exenatide once weekly relative to basal insulin among type 2 diabetes patients of different races in routine care
Diabetes Therapy Oct 09, 2017
Nunes AP, et al. - This study used real-world electronic health record (EHR) data to test exenatide once weekly (EQW) for overall efficacy and tolerability in racial/ethnically diverse patients with type 2 diabetes and results were also compared with those who received basal insulin (BI), taking into account race. Findings revealed that treatment with EQW versus BI was related to larger reductions in HbA1c and weight and reduced risk of hypoglycemia. Notably, these effects did not vary between white and African American patients.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries